or call: +31 (0)85 111 9799

Pharma 2030: Find Out More About the Main Predictions


Though the future is uncertain, one thing we know about the present stats of the pharma market, it has begun a revolution that will last for the next years. What are the main predictions for pharma in 2030? Let’s find out.

The pandemic influenced the sector regarding crisis prevention and adaptation to a new reality. In a way, COVID-19 made healthcare experts think hard about the future of medicine. Furthermore, it has made the customer-centric approach more valuable than ever.

For this to be successful pharma has an important role to play. Companies will have to find a way to customize their medical products while at the same time developing new drugs and treatment innovations. 

Yet how will pharma have evolved by the end of 2030? What will research and development look like? What are the changes that will shape the way the sector works? Will technology have a deeper impact on the sector as we know it today? 

The predictions for Pharma 2030

Data: The key to a customer-centric approach

The tendency will be more and more noticeable in pharma. Products and services will not be the two main elements to drive the needs of this market. Data analysis and action based on this review will have a bigger role to play in the coming years.

The evolution of technology will allow many pharma companies to analyze data based on their costumer’s needs and experiences. Data may very well become the main driver, seeing that the results will influence the way that medicines and treatments are developed and administered to each patient.

As AI technologies enter this conversation, the methods for measuring data will be more accurate and effective. But to get to this stage the data needs to be measured the right way. This will need time and adaptation from many healthcare workers since their work will be influenced by the results revealed.

As this analysis becomes more and more in touch with reality, data will help pharma to deliver more than medicine. Many foresee early diagnostics of diseases even before symptoms show up. The best part is that previous data will also provide relevant information to address the predicted condition.

What else will happen…

Data analysis will be more accurate and in touch with reality. A rising possibility of a variety of analyses for patient details might start with a transformation of clinical trials. The pandemic already had some effects on these procedures, yet new possibilities are rising.

In their turn, clinical trials will be more personalized based on the participant’s features and needs. In the future, trials may work based on a procedure in which several treatments are treated simultaneously. Another strong possibility is a “basket”-based model in which a drug will be tested on patients with different types of cancers. A trend that might continue for the next years is home clinical trials.

The growing role of decision-makers

Here is where the part that regulatory agencies play becomes important for the next years. A regulatory agency is necessary to facilitate the pharmaceutical industry’s efforts to bring innovation to every country. There’s also the fact that providing robust and complete information is essential to getting a medicine approved.

The obstacle here is related to the evolution of tech in pharma. Plus there’s also the fact that many future drugs may include new technologies for their measurement. This will make their approval more tricky because even though the technology is fast, integrating it into decision-making spheres will take time.

Regulatory agencies will be a part of one of the bigger challenges that pharma will have to go through to align two distinct points. During the coming years, there will have to be a series of dialogues between regulatory agencies, inventors, and users. The main goal will be to test the upcoming technologies and integrate them into decision-making.

The rapid and ongoing evolution of technology

This is the century in which technology is currently evolving faster than ever. More than one business sector has already tested and tried out the innovations which came to the market. The growing preference for a remote ambiance in more than one business will influence pharma’s methods.

As previously mentioned, there will be a strong possibility that clinical trials will be remote. This is one of many signs that show the customer-centric path pharma is headed. Thanks to the growing role of technology, patients will have more control over their health.

Organizations in that sense will have to raise awareness to teach both patients and physicians about the possibilities that they have with technology. By becoming more and more familiar with the technology that is yet to come, patients might be able to control their treatments, along with their outcomes.

For many of the predictions to successfully come true in pharma in 2030, much of present-day scientific research will have to start with the patient. Many of the methods that work today, might not have the same effect in the years to come.

What will be vital for pharma to do while it’s still adapting to the technological disruption is to discover a common space for information. The next step is to make this element available to those who need it and work all together with the products and services of the health industry.

The future, overall, will involve more and more intervening actors in the role that pharma plays in healthcare. It will also depend on the adoption of a broader approach that will bring in a variety of customized solutions that will alter the way pharma works as we know it in the present.

The future is exciting for pharma companies. However, without a doubt, video content will remain relevant. Even in the future that awaits us.

BlueNovius has got your back when it comes to video marketing solutions for pharma brands.

Discover more about PubExplainer and MedExplainer. Book your call and discover how we can help you.

Time to Take the Lead: Technology VS. Life Sciences

Why Pharma Needs to Become Customer-Centric Right Away

Closed-Loop Marketing 2.0: The Digital Disruption Enhancement